Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Treatment of JIA (1 of 2)
Understanding both the circumstances in which DMARDs should be used and which DMARD should be selected is challenging because of the heterogeneity of the disease. Treatment approaches are based on the severity of symptoms.
The goal of treatment is to reduce pain, swelling, and joint damage. Typically treatment includes nonsteroidal anti-inflammatory drugs and corticosteroids (usually as intra-articular injections but sometimes orally). This approach does not cure the disease but may significantly reduce symptoms.
Keywords: anti-rheumatic | antirheumatic | disease-modifying | DMARDs | JCA | JIA | JRA | juvenile chronic arthritis | juvenile rheumatic arthritis | rheumatic | juvenile idiopathic arthritis
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.